Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Authors

Brian Chen
Sumimasa Nagai
James O Armitage
Bartlett Witherspoon
Chadi Nabhan
Ashley C Godwin
Y Tony Yang, George Washington University
Anuhya Kommalapati
Sri Harsha Tella
Carlo DeAngelis
Dennis W Raisch
Oliver Sartor
William J Hrushesky
Paul S Ray
Paul R Yarnold
Bryan L Love
LeAnn B Norris
Kevin Knopf
Laura Bobolts
Joshua Riente
Stefano Luminari
Robert C Kane
Shamia Hoque
Charles L Bennett

Document Type

Journal Article

Publication Date

3-6-2019

Journal

The oncologist

DOI

10.1634/theoncologist.2018-0341

Comments

Epub ahead of print

APA Citation

Chen, B., Nagai, S., Armitage, J., Witherspoon, B., Nabhan, C., Godwin, A., Yang, Y., Kommalapati, A., Tella, S., DeAngelis, C., Raisch, D., Sartor, O., Hrushesky, W., Ray, P., Yarnold, P., Love, B., Norris, L., Knopf, K., Bobolts, L., Riente, J., Luminari, S., Kane, R., Hoque, S., & Bennett, C. (2019). Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.. The oncologist, (). http://dx.doi.org/10.1634/theoncologist.2018-0341

Peer Reviewed

1